Changes in Beneficial Ownership · 4
STAAR Surgical Company
STAANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-14
- Issuer
- STAAR SURGICAL CO
- Issuer CIK
- 0000718937
- Trading symbol
- STAA
Reporting owner 1
- Name
- ANDREWS DEBORAH J
- Reporting owner CIK
- 0001325697
- Relationship
- Officer
- Officer title
- Chief Financial Officer & EVP
- Address
- 25510 COMMERCENTRE DRIVE, LAKE FOREST, CA, 92630
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-14 | M · Form 4 | 5,233 | A | 0 | 41,452 | D |
| Common Stock | 2026-08-14 | F · Form 4 | 2,662[F1] | D | 26.18 | 38,910 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | 0[F2] | 2026-08-14 | A · Form 4 | 4,975 | A | 0 | [F3] | [F4] | Common Stock | 4,975 | 4,975 | D |
| Stock Option (right to buy) | 26.18 | 2026-08-14 | A · Form 4 | 8,952 | A | 0 | [F5] | 2036-08-13 | Common Stock | 8,952 | 8,952 | D |
| Performance Stock Option (right to buy) | 26.18 | 2026-08-14 | A · Form 4 | 29,159 | A | 0 | [F6] | 2036-08-13 | Common Stock | 29,159 | 29,159 | D |
| Performance Stock Units | 0 | 2026-08-14 | M · Form 4 | 5,233 | A | 0 | [F7] | 2027-12-31 | Common Stock | 5,233 | 41,452 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
Footnotes
- F1
- On May 15, 2026, the third tranche of 5,233 performance stock units ("PSUs") awarded to the Reporting Person under the 2025 PSU Program in connection with her new hire grant vested, of which 2,662 shares were withheld to satisfy taxes.↩ 1
- F2
- Each restricted stock unit ("RSU") represents the right to receive one share of STAAR Surgical Company ("Company") common stock upon vesting.↩ 1
- F3
- The Reporting Person was granted Company RSUs on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.↩ 1
- F4
- The Reporting Person was granted Issuer restricted stock units (RSUs) on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.↩ 1
- F5
- The Reporting Person was granted an option to purchase 8,952 shares of Company common stock. The shares underlying the option vest over three years from the Grant Date, with one-third vesting on the first anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installment thereafter.↩ 1
- F6
- The Reporting Person was granted a performance option to purchase 29,159 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.↩ 1
- F7
- Represents the settlement of the third tranche of PSUs awarded to the Reporting Person in connection with her new hire grant under the 2025 PSU Program. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.↩ 1
Signature 1
- Signed
- /s/ Deborah Andrews
- Date
- 2026-08-18
Company context
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for over 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding STAAR SURGICAL CONov 16, 2026
- 10-Q filingNov 4, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureNov 4, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 5, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 10, 2026